<DOC>
	<DOC>NCT00267020</DOC>
	<brief_summary>The purpose of this research study is to determine the effects and toxicity of gemcitabine alone or gemcitabine plus enzastaurin in patients with pancreatic cancer.</brief_summary>
	<brief_title>Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Patients With Advanced or Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Diagnosis of adenocarcinoma of the pancreas. Pretreatment tumor specimen must be available. No prior chemotherapy immunotherapy, biological therapy, or hormonal therapy for pancreatic cancer, including 5FU with radiation therapy. Prior radiation allowed. Ability to stop some types of antiseizure medicines within 14 days of enrollment. Endocrine pancreatic tumor or ampullary cancer. Central Nervous System metastases. Inability to swallow tablets. 10% or greater weight loss over the 6 weeks before study entry.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>